

International Journal for Advanced Review and Research in Pharmacy (IJARRP)

RP-HPLC Method Development and Validation for the Simultaneous Estimation of Metoprolol and Telmisartan in Tablet Dosage Form

K.Pranitha*, Tabassum, J.Priya, N. Rama Thilagam

M.Pharmacy, Department of Pharmaceutical Analysis, Smt.Sarojini Ramulamma College of Pharmacy, Mahabubnagar(509001), A.P. INDIA. corresponding author email id:kankanalapranitha@gmail.com

ABSTRACT

A simple reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for simultaneous determination of Metoprolol And Telmisartan in pharmaceutical tablet dosage form. Chromatographic analysis was performed on a Symmetry X-terra C8 (4.6mm x 150mm, 5µm)column at ambient temperature with a mixture of mixed Orthophosphoric acid buffer, Acetonitrile and Methanol in the ratio 45:10:45 v/v (ortho phosphoric acid buffer, Acetonitrile and Methanol in the ratio 45:10:45 v/v (ortho phosphoric acid buffer preparation; Take 1000ml of HPLC grade water. Dissolve 2.72 grams of Potassium di hydrogen phosphate salt and Adjusted the pH to 3.0 with orthophosphoric acid. as mobile phase, at a flow rate of 0.7 mL min-1. UV detection was performed at 226 nm. The method was validated for accuracy, precision, linearity and sensitivity. The retention times of Metoprolol And Telmisartan were 2.473 and 3.407 min, respectively.


Calibration plots were linear over the concentration ranges 12.5–62.5 µg mL-1 and 10-50 µg mL-1 for Metoprolol And Telmisartan, respectively. The Limit of detection was 0.66 and 0.84µg mL-1 and the quantification limit was 2.02 µg mL-1 and 2.56µg mL-1 for Metoprolol And Telmisartan, respectively. The accuracy of the proposed method was determined by recovery studies and found to be 99.93% to 101.09%. Commercial tablet formulation was successfully analyzed using the developed method and the proposed method is applicable to routine analysis of determination of Metoprolol And Telmisartan in pharmaceutical tablet dosage form.

Keywords:

Metoprolol And Telmisartan, RP-HPLC, Validation.

INTRODUCTION:

Metoprolol is chemically described as: (RS)-1- (Isopropyl amino) -3-[4-(2-methoxyethyl) phenoxy] propan-2-ol. It is used mainly in treatment of several diseases of the cardiovascular system, especially hypertension it is a beta-adrenergic receptor blocking agent.. Telmisartan is chemically described as: 2-(4-{[4-methyl-6-(1-methyl-1H-1, 3-benzodiazol-2yl)-2-propyl-1H-1, 3-benzodiazol-1-yl] methyl} phenyl) benzoic acid. It is used as antihypertensive it is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor subtype. Angiotensin II is the principal precursor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium.. Fix dosage combination containing Metoprolol (50mg) and Telmisartan (40 mg) available in market. A new combination formulation of Metoprolol and Telmisartan seems to be beneficial in the treatment and management of essential hypertension in terms of its convenience and patient compliance. Analytical method for Metoprolol is official in IP, BP and USP and Telmisartan is official in IP, BP



METOPROLOL

TELMISARTAN

MATERIALS AND METHODS:

Chemicals/ Reagents and Solvents:

Metoprolol -50mg and Telmisartan-40mg were obtained from, GLENMARK Pharmaceutical Ltd. Mumbai. Double Distilled Water (HPLC grade), Methanol(HPLC grade), Acetonitrile (HPLC grade), orthophosphoric acid and Potassium-dihydrogen phosphate were of reagent grade. The pharmaceutical preparations of combination of Metoprolol and Telmisartan that is TELMAXX 50 tablet (GLENMARK Pharmaceutical Ltd. Mumbai.).

Instrumentation and Equipments:


The HPLC analysis was accomplished on WATERS high pressure liquid chromatography outfitted with 515 reciprocating dual column HPLC pump, a manually operating Rheodyne injector with 20μ L sample loop, X-terra C8 4.6mm x 150mm analytical column reversed-phase material of 5μ size and a 2487 mod-

el UV-Visible detector. All the parameters of HPLC were controlled by N 2000 chromatographic system software. Other instruments used were TECHCOMP UV-Vis spectrophotometer of model 2310, Shimadzu electronic balance of model XEX-200, ADWA of model AD102U digital pH meter and ENERTECH of model SE60US ultrasonic bath sonicator.

ANALYTICAL METHOD DEVELOPMENT: *Optimization of UV conditions:*

A symmetry X-terra C8 (4.6mm x 150mm, 5 μ m) was used for chromatographic separation. Ther mobile phase composed of pH 3 Buffer (Orthophosphoricacid):Acetonitrile :Methanol (45:10:45) at flow rate 0.7 mL/min with run time 6mins. Mobile phase and sample solution were filtered through a 0.45 μ m membrane filter and degassed. The detection of both drugs was carried out at 226nm.

Figure-1. Isobestic point of Metoprolol And Telmisartan.



Optimized Method Parameters:

MobilePhase : Phosphate buffer (3.0 pH): Acetonitrile: Methanol (45:10:45) Column (Stationary Phase): X-terra(C8) (4.6mm x 150mm, 5µm) Flow rate (ml/min): 0.7 Column temperature (°C): Ambient Volume of injection loop (µl): 20 Detection wavelength (nm):226 Drug RT (min): Metoprolol- 2.4, Telmisartan- 3.4




Figure 1.1 Optimized chromatogram

PROCEDURE FOR PREPARATION OF SOLUTION: *Preparation of buffer:*

Take 1000ml of HPLC grade water. Dissolve 2.72 grams of Potassium di hydrogen phosphate salt and Adjusted the pH to 3.0 with orthophosphoric acid.

Preparation of mobile phase:

A mixture of above prepared buffer 450 ml (45%), 450 ml of HPLC grade Methanol and 100 mL of Acetonitrile (10%) were mixed and degassed in ultrasonic water bath for 5 minutes. The mobile phase was filterred through 0.45 μ filter under vacuum.

Diluent Preparation:

Use Mobile phase Diluent Phase

ASSAY:

Preparation of the Metoprolol And Telmisartan standard & sample solution:

Preparation of Standard Solution:

Accurately weighed and transferred 12.5 mg of Metoprolol and 10 mg of Telmisartan working standard into a 100ml clean dry volumetric flask and added about 70ml of diluent. It was sonicated to dissolve completely and made volume up to the mark with the same diluent. (Stock solution)

From this, 3 ml of the solution was pipetted into another 10 ml volumetric flask and diluted up to the mark with diluent..

Sample Solution Preparation:

Accurately weighed and transferred tablet powder equivalent to 12.5 mg of Metoprolol and 10 mg of Telmisartan (136.3 mg) into a 100ml clean dry volumetric flask and added about 70ml of diluent. It was sonicated to dissolve completely and made volume up to the mark with the same diluent. (Stock solution) From this, 3 ml of the solution was pipetted into another 10ml volumetric flask and diluted up to the mark with diluent

Procedure:

 $20 \ \mu L$ of the standard and sample solutions were injected into the chromatographic system and areas for the Metoprolol And Telmisartan peaks were measured. %Assay was calculated by using the formulae.

Calculation:

| Assay | % = | | | |
|-------|-----|-----|-----|-------------|
| AT | WS | DT | Р | Avg. Wt |
| X | X - | x - | X | X 100 |
| AS | DS | WT | 100 | Label Claim |

Where:

| AT = Average area count | s of sample preparation |
|-------------------------|-------------------------|
|-------------------------|-------------------------|

AS = Average area counts of standard preparation.

WS = Weight of working standard taken in mg.

P = Percentage purity of working standard

LC = LABEL CLAIM mg/ml.

ANALYTICAL METHOD VALIDATION

The HPLC method was validated in accordance with ICH guidelines.

Accuracy:

Accuracy was carried out by % recovery studies at three different concentration levels. To the pre-analyzed sample solution of METO and TELM a known amount of standard drug powder of METO and TELM were added at 80, 100 and 120 % level.

Precision:

The system precision of the method was verified by five replicate injections of standard solution containing METO and TELM . The method precision was carried out the analyte five times using the proposed method. Repeatability was measured by multiple injections of a homogenous sample of METO and TELM .

Linearity:

The linearity was determined separately for METO and TELM Linearity of the method was studied by injecting 5 concentrations of both drugs prepared in methanol and calibration curves were constructed by plotting peak area against the respective concentrations.

Limit of detection and Limit of quantitation:

Sensitivity of the proposed method was estimated in terms of Limit of Detection (LOD) and Limit of

| Quantitation (LOQ). LOD = $3.3 \times ASD/S$ and LOQ |
|--|
| = 10 x ASD/S, Where, 'ASD' is the average standard |
| deviation and 'S' is the slope of the line. |

Robustness:

Robustness was evaluated by making deliberate variations in method parameters such as variation of wave length; flow rate and change in mobile phase composition. The robustness of the method was studied for METO and TELM

RESULTS AND DISCUSSION:

Selection of Chromatographic Conditions and Optimization of Mobile Phase:

Mobile phase was optimized to separate METO and TELM using Symmetry C8 column (150 mm x 4.6 mm i.d., 5µm). Initially, ACN and phosphate buffer and methanol in the Equal proportions were tried as mobile phase but the splitting of the peaks for both these drugs was observed. Therefore, after adjustment of pH of mixed phosphate buffer to 3.0 with ortho-phosphoric acid, and mobile phase composition (phosphate buffer, ACN and methanol in 45:10:45 % v/v) was tried for resolution of both drugs. Good resolution and symmetric peaks were obtained for both drugs when the pH of the mobile phase (buffer) was adjusted to 3.0. The flow rate of the mobile phase was 0.7 mL min-1. Under optimum chromatographic conditions, the retention time for METO and TELM was found to be 2.473 and 3.407 min, respectively when the detection was carried out at 226nm. A typical chromatogram of two drugs is shown in (Figure 1).

| Drugs | Amount Added (mg) | Amount Found (mg) | % Recovery | % of mean recovery | |
|-------------|-------------------|-------------------|------------|--------------------|--|
| | 67.5 | 67.43 | 99.8 | | |
| Metoprolol | 75 | 76.3 | 102 | 99.93 | |
| | 82 | 81.55 | 98 | | |
| | 54 | 53.86 | 99.42 | | |
| Telmisartan | 60 | 60.41 | 101.37 | 101.09 | |
| | 66 | 66.90 | 102.50 |] | |

Table-1: ACCURACY DATA

| S.NO | RT | METOPROLOL AREA | RT | TELMISARTAN AREA | | |
|--------------------|--------|--------------------|--------|---------------------|--|--|
| 1 | 2.472 | 1745269 | 3.397 | 6017053 | | |
| 2 | 2.543 | 1744223 | 3.477 | 6061793 | | |
| 3 | 2.498 | 1755032 | 3.440 | 6084698 | | |
| 4 | 2.473 | 1745274 | 3.398 | 6017163 | | |
| 5 | 2.548 | 1744271 | 3.482 | 6061885 | | |
| Average | 2.5068 | 1746614 | 3.4388 | 6048520 | | |
| Standard Deviation | 0.0368 | 4726.359 | 0.041 | 30151.48 | | |
| % RSD | 1.4 | 0.27 | 1.2 | 0.50 | | |


Table-3 METHOD PRECISION

| S.NO | RT | AREA | RT | AREA |
|--------------------|--------|-----------|-------|----------|
| 1 | 2.490 | 1723623 | 3.423 | 5925015 |
| 2 | 2.515 | 1709983 | 3.448 | 5864329 |
| 3 | 2.492 | 1720330 | 3.418 | 5891368 |
| 4 | 2.488 | 1723516 | 3.423 | 5924883 |
| 5 | 2.498 | 1720296 | 3.423 | 5909737 |
| Average | 2.4966 | 1719549.6 | 3.427 | 5903066 |
| Standard Deviation | 0.010 | 5590.41 | 0.011 | 25688.72 |
| % RSD | 0.4 | 0.33 | 0.32 | 0.44 |

Table-4: LINEARITY RESULTS OF METOPROLOL AND TELMISARTAN

| METOPROLOL | | TELMISARTAN | |
|---------------|-----------|---------------|-----------|
| Conc (mcg/ml) | Mean Area | Conc (mcg/ml) | Mean Area |
| 12.5 | 319799 | 10 | 1677519 |
| 25 | 1003211 | 20 | 3739380 |
| 37.5 | 1755032 | 30 | 6084698 |
| 50 | 2551909 | 40 | 8174726 |
| 62.5 | 3150848 | 50 | 10315646 |

Fig 2: LINEARITY GRAPHS OF METOPROLOL AND TELMISARTAN






Table-5 LOD AND LOQ RESULTS

| S.No | Drug name | Standard deviation | Slope | LOD | LOQ |
|------|-------------|--------------------|--------|------|------|
| 1 | Metoprolol | 11659 | 57686 | 0.66 | 2.02 |
| 2 | Telmisartan | 55707 | 217116 | 0.84 | 2.56 |

Table-6: ROBUSTNESS RESULTS

| | Metoprolol | | Telmisartan | | | | |
|------|------------------------------|-------------------------------------|----------------|------------|-------------------------------------|-------------------|------------|
| S.No | Parameter | Theoretical plates per column | Tailing factor | Resolution | Theoretical plates per column | Tailing factor | Resolution |
| 1 | Less flow(0.63ml/ min) | 2122 | 1.287 | - | 4101 | 1.139 | 5.462 |
| 2 | More flow(0.77ml/ min) | 2095 | 1.295 | - | 3952 | 1.149 | 5.326 |
| 3 | %10 Less organic | 2101 | 1.255 | - | 4028 | 1.134 | 5.404 |
| 4 | %10 More organic | 2042 | 1.245 | - | 3892 | 1.124 | 5.323 |

RESULTS AND DISCUSSION

shown in Table 1.

Accuracy:

The accuracy of the method studied at three different concentration levels i.e. 80%, 100% and 120% showed acceptable % recoveries in the range of 99.93% for METO and 101.09% for TELM . The results are

Precision:

The precision study was evaluated on the basis of % RSD value was found to be in the range 0.27-1.4 and 0.32-0.4 %, respectively. As the RSD values were < 2% therefore developed method was precise. Results of

precision study are shown in Table 2 & 3.

Linearity:

The linearity was determined separately for METO and TELM .Linearity of the method was studied by injecting 5 concentrations of both drugs prepared in methanol and calibration curves were constructed by plotting peak area against the respective concentrations. The METO and TELM followed linearity in the concentration range of 12.5–62.5 μ g mL-1 and 10-50 μ g mL-1; respectively. The results are shown in Table 4.and Fig no 2.

Limit of detection and Limit of quantitation:

The LOD for METO and TELM was found to be 0.667 and 0.846 μ g, respectively. The LOQ for METO and TELM was found to be 2.021 and 2.565 μ g, respectively. The low values of LOD and LOQ indicates high sensitivity of the method. The results are shown in Table 5.

Robustness study:

Robustness of the method was studied by making deliberate changes in the chromatographic conditions and the effects on the results were examined. The low value changes of theoretical plates, tailing factor indicating robustness of the method. The results are shown in Table 6.

Analysis of marketed tablet formulation:

3 replicates of the samples solutions (20 μ L) were injected for quantitative analysis. The amounts of METO and TELM estimated were found to 99.09 % and 98.42 %, respectively. A good separation and resolution of both drugs indicates that there was no interference from the excipients commonly present in pharmaceutical formulations. The results are shown in Table 7.

System Suitability Test:

The system suitability parameters such as resolution, number of theoretical plates and tailing factor were studied and were summarized in Table 8.

Table 7:ASSAY RESULTS

| Assay Results Drug | Amount present/tablet | % of Assay |
|-----------------------|--------------------------|------------|
| METOPROLOL | 50mg | 99.09 |
| TELMISARTAN | 40 mg | 98.42 |

Table 8:SYSTEM SUITABILITY PARAMETERS

| System suitability Parameters | METOPROLOL | TELMISARTAN |
|-------------------------------------|------------|-------------|
| Tailing Factor | 1.275 | 1.145 |
| Theoritical plates | 2076 | 3997 |
| Resolution | | 5.381 |

CONCLUSION:

The developed RP-HPLC method is simple, precise, accurate, selective and reproducible. The method has been found to be adequately in linearty and robustness can be used for simultaneous determination of Metoprolol and Telmisartan in tablet formulation. The method was validated as per ICH guidelines

REFERENCES:

- 1. British Pharmacopoeia 2010, London-HMSO Publication. Vol II p.1419,1042.
- 2. Brirtish Pharmacopoeia: Medicines and Healthcare products Regulatory Agency (MHRA): Telmisartan: 5872
- 3. Indian Pharmacopoeia 2010, Governament of India, Ministry Of Health and Welfare. Published by Indian Pharmacopoeia commission, 2010, 1681-1682, 2186-2187.
- 4. The United States Pharmacopoeia: London: The United States Pharmacopoeial Convention: Metoprolol: 2007; 28(6): 1102.
- Rang H.P, Dale M.M, Ritter J.N, Moore P.K,pharmacology, 5th edn, Newyork,Churchill, Livingstone,2003,672-674.
- Laurence LB, Goodman and Gilman: The pharmacological basis of therapeutics:11th ed.: Mcgraw-hill medical publishing divisions: Metoprolol: 2006;284
- 7. Martindale The Complete Drug Reference: Telmisartan: 951.3.
- 8. A.Lakshmana Rao, Gopala Swamya, K. Nagarajub proposed RP-HPLC Method for the Simultaneous Estimation of Telmisartan and Hydrochlorothiazide in Pharmaceutical Dosage Form. International Journal of Drug Development & Research October-December 2011,Vol. 3 ,Issue 4,ISSN 0975-9344
- 9. Rambabu.kuchi, Sk.Shajhan , Sarath Chandra reddy, proposed RP-HPLC method for estimation of metoprolol in bulk drug. International Journal of Science Innovations and Discoveries Vol 1, Issue 2, September-October 2011 P.no. 151-157
- S.Brijesh, D. Pateland S. Ghosh, Development of Reverse-Phase HPLC Method for Simultaneous Analysis of Metoprolol Succinate

and Hydrochlorothiazide in a Tablet Formulation,Tropical Journal of Pharmaceutical Research, 2009; Dec; 8 (6): 539-43.

- 11. A.Gadhavi, C.Patel, R.Parmar, V.Shah and D.Shah,simultaneous estimation of Telmisartan and Metoprolol Succinate in pharmaceutical dosage form by simultaneous equation method, IJIPLS,2012
- 12. Prajakta S.Nawle et al; proposed normal and reverse phase HPTLC methods for simultaneous estimation of Telmisartan and Metoprolol succinate in pharmaceutical formulations. ISRN Analytical Chemistry Volume 2012, Article ID 815353, 6 pages
- 13. Suresh Kumar GV, Rajendraprasad. proposed Development And Validation of Reversephase HPLC Method for Simultaneous Estimation Of Telmisartan And Amlodipine InTablet Dosage Form Int J Pharmacy Pharm Sci Vol 2, Issue 3, 2010 p.no 128-131.
- Patel AR, Chandrul KK. Method development, validation and stability study for simultaneous estimation of Telmisartan and Indapamideby RP-HPLC in pure and marketed formulations. Int J Pharm And Biomed Res. 2011 2(1): 4-16. [Available from http://www.kejapub.com/ijpbr/ docs/IJPBR11-02-01-10.pdf]
- 15. Sunil Jawla et al;,,developed development and validation of HPLC method for the simultaneous estimation of Telmisartan & Ramipril in pharmaceutical formulations. International Journal of PharmTech Research 2010,2(2) 1625-1633
- Dr.Sujit pilli and Deepmala manore et al; proposed simultaneous spectrophotometric estimation of Telmisartan and Metoprolol succinate in bulk and tablet dosage forms.IJPT 2012 vol4 (4090-4099)